GSK is quietly building a new treatment pipeline, in parallel to its established work on molecular medicines, that hopes to use peoples’ nerves to treat disease. If successful, it could not only revolutionize its product offering, but change the very way we think of medicine.

from Forbes – Tech http://ift.tt/1PKnm6O
via IFTTT